Business
Cencora Accelerates OneOncology Acquisition, Extending Solutions Offering for Community Oncology
CONSHOHOCKEN, Pa., December 15, 2025--Cencora, Inc. (NYSE: COR) today announced it has entered into a definitive agreement to acquire the majority of the outstanding equity interests that it does not currently own in OneOncology, a physician-led national platform empowering independent medical specialty practices rooted in oncology, from TPG, a leading global alternative asset management firm.
About this update from Cencora, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Company reiterates fiscal 2026 guidance","length":39,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Company raises long-term guidance expectations to reflect OneOncology’s expected long-term contribution to enterprise growth","length":124,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":163,"olType":false},{"type":"text","content":"CONSHOHOCKEN, Pa., December 15, 2025--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced it has entered into a definitive agreement to acquire the majority of the outstanding equity interests that it does not currently own in OneOncology, a physician-led national platform empowering independent medical specialty practices rooted in oncology, from TPG, a leading global alternative asset management firm.","length":413,"tagName":"p"},{"type":"text","content":""We are excited to accelerate our acquisition of OneOncology, which will advance our management services organization and aligns with our approach of making growth-oriented investments that support our pharmaceutical-centric strategy," said Bob Mauch, President & CEO of Cencora. "Since our initial investment in OneOncology, the platform has grown substantially as its physician-led approach continues to attract leading practices and physicians, supporting patient access to high-quality care in local communities. With our recent acquisition of RCA, we look forward to building on both platforms’ research and clinical trial capabilities, advanced technology resources and strong physician leadership to drive unique value to our stakeholders."","length":771,"tagName":"p"},{"type":"text","content":""We are pleased to advance our longstanding partnership with Cencora, who shares our commitment to supporting independent providers," said Jeff Patton, M.D., Chief Executive Officer of OneOncology. "As cancer care becomes increasingly complex, leveraging the significant expertise of Cencora across the healthcare landscape, while still maintaining our independence, will allow us to enhance the value we provide to practices, improving physicians’ ability to focus on delivering accessible and innovative care to their patients."","length":550,"tagName":"p"},{"type":"text","content":"The proposed transaction will build on Cencora’s pharmaceut...